The Opportunity:
What's in the Package
More than a promising technology. A comprehensive development package built around Bismocin, ready to support the next steps towards clinical development.
01
Intellectual Property
Two patent applications covering a proprietary dry powder inhalation formulation and a novel bismuth-based composition designed to potentially sustain therapeutic effectiveness over time.
02
Preclinical Data Package
Extensive in vitro and in vivo pharmacology, efficacy and safety data supporting the development of Bismocin.
03
CMC Package
A largely completed CMC development program, including formulation, analytical methods and manufacturing documentation.
04
Clinical Development Strategy
A defined clinical development roadmap, with a potential US 505(b)(2) regulatory pathway and eligibility for FDA Fast Track and QIDP designations.
05
Regulatory Documentation
Positive Germany's BfArM scientific advice supporting the proposed preclinical development program, including a streamlined toxicology strategy involving a single animal species.
06
Formulation & Delivery Technology
A proprietary dry powder formulation developed for pulmonary administration using the Cyclops® dry powder inhaler.
Established clinical experience. Targeted delivery. Encouraging preclinical safety.
A Clear Path Forward
Bismocin is at an advanced stage of preclinical development, supported by extensive in vitro and in vivo efficacy and safety data. CMC development is largely completed, with GMP manufacturing among the principal remaining activities.
The proposed preclinical development program has received positive scientific advice from Germany's Federal Institute for Drugs and Medical Devices (BfArM), including support for a toxicology strategy involving a single animal species rather than the conventional two-species approach.
The remaining development activities are well defined, primarily comprising GMP batch manufacturing, final toxicology studies and pulmonary safety pharmacology.
With appropriate development resources, the remaining preclinical milestones are anticipated to be completed within 12 months.
12 Months to Preclinical Milestones
A defined development roadmap, supported by positive BfArM scientific advice and a streamlined preclinical program.
In the United States, the development strategy includes the FDA's 505(b)(2) regulatory pathway, with opportunities for QIDP designation and Fast Track status.
A clear route towards clinical development, with remaining preclinical milestones targeted for completion within 12 months.
Acquisition & Licensing Opportunities
Omnicin Therapeutics is seeking a buyer for the Bismocin™ program, offering an opportunity to acquire a differentiated therapeutic asset with substantial preclinical development already completed.
Our preferred transaction is a full acquisition, enabling the buyer to assume ownership and responsibility for further development and commercialization.
Both a company acquisition and a direct asset acquisition can be considered. Exclusive licensing remains an alternative.
A Confidential & Structured Process
Omnicin offers a straightforward and confidential process for parties interested in acquiring or licensing the Bismocin program.
01
Initial Enquiry
Interested parties are invited to contact Omnicin to express their interest in the opportunity.
02
NDA & Confidential Information Memorandum
Following execution of a non-disclosure agreement (NDA), a Confidential Information Memorandum (CIM) will be provided, outlining the Bismocin program, its development status, intellectual property and commercial potential.
03
Management Discussion
A follow-up meeting provides an opportunity to discuss the program in greater detail, address initial questions and explore potential transaction structures.
04
Virtual Data Room & Due Diligence
Qualified parties wishing to proceed may be granted access to a secure virtual data room containing detailed scientific, preclinical, CMC, regulatory and intellectual property documentation.
05
Transaction Agreement & Closing
Following successful due diligence and agreement on commercial terms, the transaction will be formalized through a definitive acquisition or licensing agreement, followed by closing and transfer of the agreed rights and assets.